Yoh K - Search Results

1

Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations.

Saruwatari K, Ikemura S, Sekihara K, Kuwata T, Fujii S, Umemura S, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Ochiai A, Kohrogi H, Tsuboi M, Goto K, Ishii G. Saruwatari K, et al. Among authors: yoh k. Lung Cancer. 2016 Jan;91:7-14. doi: 10.1016/j.lungcan.2015.11.012. Epub 2015 Nov 15. Lung Cancer. 2016. PMID: 26711928

2

Weekly chemotherapy with cisplatin, vincristine, doxorubicin, and etoposide is an effective treatment for advanced thymic carcinoma.

Yoh K, Goto K, Ishii G, Niho S, Ohmatsu H, Kubota K, Kakinuma R, Nagai K, Suga M, Nishiwaki Y. Yoh K, et al. Cancer. 2003 Sep 1;98(5):926-31. doi: 10.1002/cncr.11606. Cancer. 2003. PMID: 12942558 Free article.

3

Cushing's syndrome associated with adenocarcinoma of the lung.

Yoh K, Kubota K, Nomura M, Niho S, Goto K, Ohmatsu H, Kakinuma R, Nishiwaki Y. Yoh K, et al. Intern Med. 2003 Sep;42(9):831-3. doi: 10.2169/internalmedicine.42.831. Intern Med. 2003. PMID: 14518671 Free article.

4

Breast cancer resistance protein impacts clinical outcome in platinum-based chemotherapy for advanced non-small cell lung cancer.

Yoh K, Ishii G, Yokose T, Minegishi Y, Tsuta K, Goto K, Nishiwaki Y, Kodama T, Suga M, Ochiai A. Yoh K, et al. Clin Cancer Res. 2004 Mar 1;10(5):1691-7. doi: 10.1158/1078-0432.ccr-0937-3. Clin Cancer Res. 2004. PMID: 15014021

5

High body mass index correlates with increased risk of venous irritation by vinorelbine infusion.

Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, Nishiwaki Y. Yoh K, et al. Jpn J Clin Oncol. 2004 Apr;34(4):206-9. doi: 10.1093/jjco/hyh029. Jpn J Clin Oncol. 2004. PMID: 15121757

6

Primary lung carcinoma with signet-ring cell carcinoma components: clinicopathological analysis of 39 cases.

Tsuta K, Ishii G, Yoh K, Nitadori J, Hasebe T, Nishiwaki Y, Endoh Y, Kodama T, Nagai K, Ochiai A. Tsuta K, et al. Among authors: yoh k. Am J Surg Pathol. 2004 Jul;28(7):868-74. doi: 10.1097/00000478-200407000-00004. Am J Surg Pathol. 2004. PMID: 15223955

7

First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study.

Niho S, Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R, Saijo N, Nishiwaki Y. Niho S, et al. Among authors: yoh k. J Clin Oncol. 2006 Jan 1;24(1):64-9. doi: 10.1200/JCO.2005.02.5825. J Clin Oncol. 2006. PMID: 16382114 Clinical Trial.

8

Interstitial shadow on chest CT is associated with the onset of interstitial lung disease caused by chemotherapeutic drugs.

Niho S, Goto K, Yoh K, Kim YH, Ohmatsu H, Kubota K, Saijo N, Nishiwaki Y. Niho S, et al. Among authors: yoh k. Jpn J Clin Oncol. 2006 May;36(5):269-73. doi: 10.1093/jjco/hyl021. Epub 2006 May 15. Jpn J Clin Oncol. 2006. PMID: 16702163

9

Eg5 expression is closely correlated with the response of advanced non-small cell lung cancer to antimitotic agents combined with platinum chemotherapy.

Saijo T, Ishii G, Ochiai A, Yoh K, Goto K, Nagai K, Kato H, Nishiwaki Y, Saijo N. Saijo T, et al. Among authors: yoh k. Lung Cancer. 2006 Nov;54(2):217-25. doi: 10.1016/j.lungcan.2006.06.018. Epub 2006 Aug 24. Lung Cancer. 2006. PMID: 16934364

10

Randomized trial of drip infusion versus bolus injection of vinorelbine for the control of local venous toxicity.

Yoh K, Niho S, Goto K, Ohmatsu H, Kubota K, Kakinuma R, Saijo N, Nishiwaki Y. Yoh K, et al. Lung Cancer. 2007 Mar;55(3):337-41. doi: 10.1016/j.lungcan.2006.10.016. Epub 2006 Nov 28. Lung Cancer. 2007. PMID: 17126951 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

415 results

Search Page

Filters